{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:21:06Z","timestamp":1792095666711,"version":"4.4.0"},"reference-count":39,"publisher":"Bioscientifica","issue":"12","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence of their association with gallbladder, biliary diseases, and liver injury remains inconsistent. This study evaluated the association between incretin therapies and hepatobiliary adverse events using the FDA\u2019s Adverse Event Reporting System (FAERS) data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Case reports involving incretin therapies and hepatobiliary events from January 2006 to December 2023 were extracted from FAERS. The association between these agents and hepatobiliary adverse events (hAEs) was analyzed using reporting odds ratios and empirical Bayesian geometric means. Descriptive analyses were conducted to characterize the demographic and clinical features of the hAE cases. Additionally, subgroup analyses calculated reporting odds ratios to evaluate the strength of the association between specific incretin drugs and hAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 68,351 case reports associated with incretin-based therapies, 1327 (1.941%) involved hepatobiliary adverse events. DPP-4 inhibitors demonstrated statistically significant associations with multiple hepatobiliary events, like cholelithiasis, chronic cholecystitis, and biliary diseases. In contrast, GLP-1 receptor agonists showed weaker associations, primarily linked to gallbladder and biliary disease risks. Subgroup analyses revealed stronger positive correlations with hepatobiliary events for liraglutide and semaglutide among GLP-1 agonists, and for sitagliptin, linagliptin, and vildagliptin among DPP-4 inhibitors. The pooled reporting odds ratio of 2.85 indicated a positive correlation between these drugs and studied adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study found statistically significant associations between DPP-4 inhibitors and hepatobiliary adverse events like cholelithiasis and cholecystitis. GLP-1 agonists showed weaker gallbladder\/biliary disorder links but higher acute cholecystitis risk. Subgroup analyses revealed varying correlations among specific drugs, potentially dose-dependent. Further large-scale studies are needed to evaluate class effect differences and elucidate mechanisms for guiding clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-24-0404","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:01:12Z","timestamp":1728990072000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":5,"title":["Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system"],"prefix":"10.1530","volume":"13","author":[{"given":"Yankun","family":"Liang","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Jinan University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpo","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Jinan University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Jinan University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Jinan University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"He","sequence":"additional","affiliation":[{"name":"Guangdong Food and Drug Vocational College, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanzhi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0594-9181","authenticated-orcid":true,"given":"Ling","family":"Su","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Jinan University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Lancet","first-page":"203","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease study 2021","volume":"402","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease study 2021. Lancet 2023 402 203\u2013234. (https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6)"},{"key":"bib2","series-title":"Diabetologia","first-page":"1925","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","unstructured":"Davies MJAroda VRCollins BSGabbay RAGreen JMaruthur NMRosas SEDel Prato SMathieu CMingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022 65 1925\u20131966. (https:\/\/doi.org\/10.1007\/s00125-022-05787-2)"},{"key":"bib3","series-title":"Diabetes, Obesity and Metabolism","first-page":"2159","article-title":"Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017","volume":"20","author":"Curtis","year":"2018","unstructured":"Curtis HJDennis JMShields BMWalker AJBacon SHattersley ATJones AG & Goldacre B. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism 2018 20 2159\u20132168. (https:\/\/doi.org\/10.1136\/10.1111\/dom.13346)"},{"key":"bib4","series-title":"JAMA Internal Medicine","first-page":"513","article-title":"Association of glucagon-like Peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","unstructured":"He LWang JPing FYang NHuang JLi YXu LLi W & Zhang H. Association of glucagon-like Peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine 2022 182 513\u2013519. (https:\/\/doi.org\/10.1136\/10.1001\/jamainternmed.2022.0338)"},{"key":"bib5","series-title":"Diabetes Research and Clinical Practice","first-page":"108087","article-title":"Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: an updated meta-analysis of randomized controlled trials","volume":"161","author":"Nreu","year":"2020","unstructured":"Nreu BDicembrini ITinti FMannucci E & Monami M. Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: an updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice 2020 161 108087. (https:\/\/doi.org\/10.1016\/j.diabres.2020.108087)"},{"key":"bib6","series-title":"Current Problems in Cardiology","first-page":"102403","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients","volume":"49","author":"Singh","year":"2024","unstructured":"Singh SGarg ATantry USBliden KGurbel PA & Gulati M. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. Current Problems in Cardiology 2024 49 102403. (https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102403)"},{"key":"bib7","series-title":"Diabetes, Obesity and Metabolism","first-page":"1233","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","unstructured":"Monami MNreu BScatena ACresci BAndreozzi FSesti G & Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes, Obesity and Metabolism 2017 19 1233\u20131241. (https:\/\/doi.org\/10.1136\/10.1111\/dom.12926)"},{"key":"bib8","series-title":"BMJ","first-page":"k4880","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"Abrahami","year":"2018","unstructured":"Abrahami DDouros AYin HYu OHFaillie J-LMontastruc FPlatt RWBouganim N & Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018 363 k4880. (https:\/\/doi.org\/10.1136\/bmj.k4880)"},{"key":"bib9","series-title":"Journal of Clinical Pharmacy and Therapeutics","first-page":"116","article-title":"Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database","volume":"41","author":"Pizzimenti","year":"2016","unstructured":"Pizzimenti VGiandalia ACucinotta DRusso GTSmits MCutroneo PM & Trifir\u00f2 G. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. Journal of Clinical Pharmacy and Therapeutics 2016 41 116\u2013118. (https:\/\/doi.org\/10.1136\/10.1111\/jcpt.12373)"},{"key":"bib10","series-title":"JAMA Internal Medicine","first-page":"1474","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","unstructured":"Faillie J-LYu OHYin HHillaire-Buys DBarkun A & Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Internal Medicine 2016 176 1474\u20131481. (https:\/\/doi.org\/10.1136\/10.1001\/jamainternmed.2016.1531)"},{"key":"bib11","series-title":"Diabetes Care","first-page":"e72","article-title":"Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"46","author":"He","year":"2023","unstructured":"He LWang JLi ZLi Y & Zhang H. Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. Food and Drug Administration Adverse Event Reporting System. Diabetes Care 2023 46 e72\u2013e73. (https:\/\/doi.org\/10.1136\/10.2337\/dc22-1095)"},{"key":"bib12","series-title":"PeerJ","first-page":"e1753","article-title":"Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model","volume":"4","author":"Narushima","year":"2016","unstructured":"Narushima DKawasaki YTakamatsu S & Yamada H. Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model. PeerJ 2016 4 e1753. (https:\/\/doi.org\/10.1136\/10.7717\/peerj.1753)"},{"key":"bib13","series-title":"Frontiers in Public Health","first-page":"1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","unstructured":"Cai WZhang RYao YWu Q & Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health 2024 12 1277113. (https:\/\/doi.org\/10.1136\/10.3389\/fpubh.2024.1277113)"},{"key":"bib14","series-title":"Diabetes, Metabolic Syndrome and Obesity","first-page":"241","article-title":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients","volume":"8","author":"MacConell","year":"2015","unstructured":"MacConell LGurney KMalloy JZhou M & Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes, Metabolic Syndrome and Obesity 2015 8 241\u2013253. (https:\/\/doi.org\/10.1136\/10.2147\/DMSO.S77290)"},{"key":"bib15","series-title":"BMJ","first-page":"e068882","article-title":"Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials","volume":"377","author":"He","year":"2022","unstructured":"He LWang JPing FYang NHuang JLi WXu LZhang H & Li Y. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ 2022 377 e068882. (https:\/\/doi.org\/10.1136\/bmj-2021-068882)"},{"key":"bib16","series-title":"Diabetes Care","first-page":"2289","article-title":"Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","unstructured":"Pradhan RYin HYu OHY & Azoulay L. Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes. Diabetes Care 2022 45 2289\u20132298. (https:\/\/doi.org\/10.1136\/10.2337\/dc22-0712)"},{"key":"bib17","series-title":"BMJ Open Diabetes Research and Care","first-page":"e000400","article-title":"Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes","volume":"5","author":"Lo Re","year":"2017","unstructured":"Lo Re VCarbonari DMSaine MENewcomb CWRoy JALiu QWu QCardillo SHaynes KKimmel SE, et al. Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Research and Care 2017 5 e000400. (https:\/\/doi.org\/10.1136\/bmjdrc-2017-000400)"},{"key":"bib18","series-title":"Clinical Therapeutics","first-page":"e106","article-title":"Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the us-fda adverse event reporting system","volume":"37","author":"Raschi","year":"2015","unstructured":"Raschi EPoluzzi EKoci AAntonazzo IC & Ponti FD. Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the us-fda adverse event reporting system. Clinical Therapeutics 2015 37 e106. (https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.306)"},{"key":"bib19","series-title":"Scientific Data","first-page":"160026","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","unstructured":"Banda JMEvans LVanguri RSTatonetti NPRyan PB & Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Scientific Data 2016 3 160026. (https:\/\/doi.org\/10.1136\/10.1038\/sdata.2016.26)"},{"key":"bib20","series-title":"Pharmacoepidemiology and Drug Safety","first-page":"427","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","unstructured":"Bate A & Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety 2009 18 427\u2013436. (https:\/\/doi.org\/10.1136\/10.1002\/pds.1742)"},{"key":"bib21","series-title":"Drug Safety","first-page":"381","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","unstructured":"Szarfman AMachado SG & O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Safety 2002 25 381\u2013392. (https:\/\/doi.org\/10.1136\/10.2165\/00002018-200225060-00001)"},{"key":"bib22","series-title":"The American Journal of Cardiology","first-page":"1577","article-title":"Contemporary trends in prescription of dipeptidyl peptidase-4 inhibitors in the context of US Food and Drug Administration warnings of heart failure risk","volume":"125","author":"Vaduganathan","year":"2020","unstructured":"Vaduganathan MSingh ASharma AJanuzzi JLScirica BMButler JZannad FMcGuire DKCannon CP & Bhatt DL. Contemporary trends in prescription of dipeptidyl peptidase-4 inhibitors in the context of US Food and Drug Administration warnings of heart failure risk. The American Journal of Cardiology 2020 125 1577\u20131581. (https:\/\/doi.org\/10.1016\/j.amjcard.2020.01.053)"},{"key":"bib23","series-title":"JAMA Cardiology","first-page":"126","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical Trial","volume":"1","author":"McGuire","year":"2016","unstructured":"McGuire DKVan de Werf FArmstrong PWStandl EKoglin JGreen JBBethel MACornel JHLopes RDHalvorsen S, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical Trial. JAMA Cardiology 2016 1 126\u2013135. (https:\/\/doi.org\/10.1136\/10.1001\/jamacardio.2016.0103)"},{"key":"bib24","series-title":"New England Journal of Medicine","first-page":"11","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer XAstrup AFujioka KGreenway FHalpern AKrempf MLau DCWle Roux CWViolante Ortiz RJensen CB, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015 373 11\u201322. (https:\/\/doi.org\/10.1136\/10.1056\/NEJMoa1411892)"},{"key":"bib25","series-title":"Lancet","first-page":"1399","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","unstructured":"le Roux CWAstrup AFujioka KGreenway FLau DCWVan Gaal LOrtiz RVWilding JPHSkj\u00f8th TVManning LS, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017 389 1399\u20131409. (https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7)"},{"key":"bib26","series-title":"International Immunology","first-page":"417","article-title":"CD26\/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response","volume":"11","author":"Iwata","year":"1999","unstructured":"Iwata SYamaguchi NMunakata YIkushima HLee JFHosono OSchlossman SF & Morimoto C. CD26\/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. International Immunology 1999 11 417\u2013426. (https:\/\/doi.org\/10.1136\/10.1093\/intimm\/11.3.417)"},{"key":"bib27","series-title":"Diabetes Care","first-page":"e198","article-title":"Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient","volume":"37","author":"Kurita","year":"2014","unstructured":"Kurita NIto TShimizu SHirata T & Uchihara H. Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient. Diabetes Care 2014 37 e198\u2013e199. (https:\/\/doi.org\/10.1136\/10.2337\/dc14-1252)"},{"key":"bib28","series-title":"The New England Journal of Medicine","first-page":"1327","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","unstructured":"White WBCannon CPHeller SRNissen SEBergenstal RMBakris GLPerez ATFleck PRMehta CRKupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England Journal of Medicine 2013 369 1327\u20131335. (https:\/\/doi.org\/10.1136\/10.1056\/NEJMoa1305889)"},{"key":"bib29","series-title":"The New England Journal of Medicine","first-page":"1317","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","unstructured":"Scirica BMBhatt DLBraunwald ESteg PGDavidson JHirshberg BOhman PFrederich RWiviott SDHoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine 2013 369 1317\u20131326. (https:\/\/doi.org\/10.1136\/10.1056\/NEJMoa1307684)"},{"key":"bib30","series-title":"Hepatology","first-page":"648","article-title":"Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk","volume":"57","author":"Chaiteerakij","year":"2013","unstructured":"Chaiteerakij RYang JDHarmsen WSSlettedahl SWMettler TAFredericksen ZSKim WRGores GJRoberts ROOlson JE, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013 57 648\u2013655. (https:\/\/doi.org\/10.1136\/10.1002\/hep.26092)"},{"key":"bib31","series-title":"Annals of Internal Medicine","first-page":"1029","article-title":"Contributions of obesity and weight loss to gallstone disease","volume":"119","author":"Everhart","year":"1993","unstructured":"Everhart JE. Contributions of obesity and weight loss to gallstone disease. Annals of Internal Medicine 1993 119 1029\u20131035. (https:\/\/doi.org\/10.1136\/10.7326\/0003-4819-119-10-199311150-00010)"},{"key":"bib32","series-title":"European Journal of Gastroenterology and Hepatology","first-page":"1347","article-title":"Gallstones in obesity and weight loss","volume":"12","author":"Erlinger","year":"2000","unstructured":"Erlinger S. Gallstones in obesity and weight loss. European Journal of Gastroenterology and Hepatology 2000 12 1347\u20131352. (https:\/\/doi.org\/10.1136\/10.1097\/00042737-200012120-00015)"},{"key":"bib33","series-title":"Gastroenterology","first-page":"244","article-title":"Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis","volume":"133","author":"Marzioni","year":"2007","unstructured":"Marzioni MAlpini GSaccomanno SCandelaresi CVenter JRychlicki CFava GFrancis HTrozzi LGlaser S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007 133 244\u2013255. (https:\/\/doi.org\/10.1136\/10.1053\/j.gastro.2007.04.007)"},{"key":"bib34","series-title":"Gut","first-page":"990","article-title":"Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis","volume":"58","author":"Marzioni","year":"2009","unstructured":"Marzioni MAlpini GSaccomanno SCandelaresi CVenter JRychlicki CFava GFrancis HTrozzi L & Benedetti A. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009 58 990\u2013997. (https:\/\/doi.org\/10.1136\/gut.2008.150870)"},{"key":"bib35","series-title":"Regulatory Peptides","first-page":"77","article-title":"Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects","volume":"179","author":"Keller","year":"2012","unstructured":"Keller JTrautmann MEHaber HTham LSHunt TMace K & Linnebjerg H. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regulatory Peptides 2012 179 77\u201383. (https:\/\/doi.org\/10.1016\/j.regpep.2012.08.005)"},{"key":"bib36","series-title":"Journal of Clinical Pharmacology","first-page":"1322","article-title":"Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study","volume":"57","author":"Shaddinger","year":"2017","unstructured":"Shaddinger BCYoung MABilliard JCollins DAHussaini A & Nino A. Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study. Journal of Clinical Pharmacology 2017 57 1322\u20131329. (https:\/\/doi.org\/10.1136\/10.1002\/jcph.940)"},{"key":"bib37","series-title":"Diabetes, Obesity and Metabolism","first-page":"2557","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nex\u00f8e-Larsen","year":"2018","unstructured":"Nex\u00f8e-Larsen CCS\u00f8rensen PHHausner HAgersnap MBaekdal MBr\u00f8nden AGustafsson LNSonne DPVedtofte LVilsb\u00f8ll T, et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes, Obesity and Metabolism 2018 20 2557\u20132564. (https:\/\/doi.org\/10.1136\/10.1111\/dom.13420)"},{"key":"bib38","series-title":"Diabetes, Obesity and Metabolism","first-page":"1217","article-title":"Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients","volume":"18","author":"Smits","year":"2016","unstructured":"Smits MMTonneijck LMuskiet MHAHoekstra TKramer MHHDiamant MNieuwdorp MGroen AKCahen DL & van Raalte DH. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes, Obesity and Metabolism 2016 18 1217\u20131225. (https:\/\/doi.org\/10.1136\/10.1111\/dom.12748)"},{"key":"bib39","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2463","article-title":"New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs","volume":"104","author":"Gether","year":"2019","unstructured":"Gether IMNex\u00f8e-Larsen C & Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. Journal of Clinical Endocrinology and Metabolism 2019 104 2463\u20132472. (https:\/\/doi.org\/10.1136\/10.1210\/jc.2018-01008)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/13\/12\/EC-24-0404.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/13\/12\/EC-24-0404.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/13\/12\/EC-24-0404.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:47:28Z","timestamp":1784555248000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":39,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/ec-24-0404","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}